ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fluticasone

Also written as “Fluticasone Propionate”, “Fluticasone propionate” and “Fluticasone Propionate/Formoterol Fumarate”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Rhinitis, Allergic, Perennial, led by 24 companies.

Drug pageFluticasone: every studyMany companies study it; this page follows only the 150 they lead. All 340 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 1, 2005150 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only580 open or runningphase 4since Feb 1, 2005Feb 1, 2005none ahead
Respirent Pharmaceuticalsits history only182 open or runningphase 3since Sep 17, 2018Sep 17, 2018none ahead
Teva Pharmaceutical Industriesits history only140 open or runningphase 4since Dec 11, 2020Nov 22, 2011none ahead
Viatris130 open or runningphase 4since Dec 16, 2016Nov 21, 2006none ahead
Optinose USits history only101 open or runningphase 3since Jun 13, 2012Jun 13, 2012Mar 31, 2028phase 3 · NCT06850805
Mundipharmaits history only60 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
SkyePharmaits history only50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratoriosits history only31 open or runningphase 3since Sep 14, 2010Sep 14, 2010Aug 2028phase 3 · NCT06234345
Merckits history only30 open or runningphase 2since Oct 5, 2006Oct 5, 2006none ahead
Hikma Pharmaceuticalsits history only20 open or runningno phasesince Jan 5, 2016Jan 5, 2016none ahead

Also a collaborator on its studies: Paratek Pharmaceuticals, Becro, Prolytic, Dynamic Solutions, Parexel, Vectura and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Viatris only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 21, 2006First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT00403286 · 457 enrolled · United States
  2. Aug 22, 2008Phase 3 study in Rhinitis, Allergic, SeasonalNCT00740792 · 776 enrolled · United States
  3. Oct 16, 2008Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT00774761 · 97 enrolled · United States
  4. Apr 16, 2009Phase 3 study in Rhinitis, Allergic, SeasonalNCT00883168 · 1,791 enrolled · United States
  5. Jul 21, 2010Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT01168310 · 468 enrolled · United States
  6. Aug 25, 2010Phase 1 study in Rhinitis, AllergicNCT01190852 · 30 enrolled · Germany
  7. Sep 2, 2010Phase 1 study in Rhinitis, AllergicNCT01194622 · 30 enrolled · Germany
  8. Jan 13, 20122 phase 2 studies in AsthmaNCT01516086, NCT01516073
  9. Feb 15, 2013Phase 3 study in Rhinitis, AllergicNCT01794741 · 405 enrolled · United States
  10. Aug 1, 2013Phase 3 study in Rhinitis, Allergic, SeasonalNCT01915823 · 348 enrolled · United States
  11. Aug 5, 2014Phase 1 study in AsthmaNCT02215122 · 40 enrolled · United States
  12. Dec 16, 2016Phase 4 study in Rhinitis, Allergic, SeasonalNCT03004131 · 82 enrolled · Canada

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 Viatris leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03004131Rhinitis, Allergic, Seasonal · Canada4CompletedMar 29, 201782
NCT02215122Asthma · United States1CompletedNov 201340
NCT01915823Rhinitis, Allergic, Seasonal · United States3CompletedFeb 2014348
NCT01794741Rhinitis, Allergic · United States3CompletedNov 2013405
NCT01516086Asthma · United States2CompletedNov 2013498
NCT01516073Asthma · United States2CompletedNov 2013629
NCT01194622Rhinitis, Allergic · Germany1CompletedOct 201030
NCT01190852Rhinitis, Allergic · Germany1CompletedOct 201030
NCT01168310Pulmonary Disease, Chronic Obstructive · United States2CompletedAug 2010468
NCT00883168Rhinitis, Allergic, Seasonal · United States3CompletedJul 20091,791
NCT00774761Pulmonary Disease, Chronic Obstructive · United States2CompletedApr 200997
NCT00740792Rhinitis, Allergic, Seasonal · United States3CompletedNov 2008776
NCT00403286Pulmonary Disease, Chronic Obstructive · United States2CompletedMay 2007457

How it is read

Names in the registry

  • “Fluticasone Propionate”, 17 entries
  • “Fluticasone propionate”, 13 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “fluticasone propionate”, 7 entries
  • “fluticasone propionate/salmeterol”, 7 entries

Codes read as this program: NCX4251, FP100.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.